Alterity Therapeutics Limited (ASX:ATH)
Australia · Delayed Price · Currency is AUD 0.4600
-0.0200 (-4.17%)
Sep 11, 2026, 11:20 AM AEST
Alterity Therapeutics Balance Sheet
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Cash & Equivalents | 37.32 | 33.16 | 12.64 | 15.77 | 34.81 |
Short-Term Investments | - | 7.5 | - | - | - |
Cash & Short-Term Investments | 37.32 | 40.66 | 12.64 | 15.77 | 34.81 |
Cash Growth | -8.22% | 221.70% | -19.87% | -54.68% | 23.80% |
Accounts Receivable | 7.54 | 3.93 | 4.02 | 8.65 | 4.67 |
Other Receivables | 0.16 | 0.01 | 0.02 | 0.02 | 0.06 |
Receivables | 7.7 | 3.94 | 4.04 | 8.67 | 4.73 |
Prepaid Expenses | 0.77 | 1.23 | 2.32 | 2.57 | 1.6 |
Other Current Assets | 0.04 | 0.04 | 0.04 | 0.04 | 0.01 |
Total Current Assets | 45.83 | 45.87 | 19.04 | 27.05 | 41.14 |
Property, Plant & Equipment | 0.19 | 0.16 | 0.19 | 0.27 | 0.22 |
Total Assets | 46.02 | 46.03 | 19.22 | 27.32 | 41.36 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Accounts Payable | 1.12 | 0.54 | 0.58 | 1.72 | 2.66 |
Accrued Expenses | 1.92 | 2.89 | 4.56 | 2.5 | 3.02 |
Current Portion of Leases | 0.06 | 0.07 | 0.11 | 0.11 | 0.06 |
Current Income Taxes Payable | 0.05 | 0.02 | 0.02 | 0.03 | 0.03 |
Other Current Liabilities | 0.02 | 0.02 | 0.11 | 0.03 | 0.06 |
Total Current Liabilities | 3.16 | 3.53 | 5.37 | 4.38 | 5.82 |
Long-Term Leases | 0.14 | 0.09 | 0.05 | 0.1 | 0.06 |
Other Long-Term Liabilities | - | -0 | - | 0.02 | 0.01 |
Total Liabilities | 3.29 | 3.62 | 5.43 | 4.5 | 5.89 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Common Stock | 282.51 | 262.95 | 223.15 | 213.97 | 213.79 |
Retained Earnings | -245.58 | -225.89 | -214.16 | -195.13 | -181.88 |
Comprehensive Income & Other | 5.8 | 5.34 | 4.81 | 3.97 | 3.57 |
Shareholders' Equity | 42.72 | 42.4 | 13.8 | 22.81 | 35.47 |
Total Liabilities & Equity | 46.02 | 46.03 | 19.22 | 27.32 | 41.36 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Total Debt | 0.19 | 0.16 | 0.16 | 0.21 | 0.12 |
Net Cash (Debt) | 37.12 | 40.5 | 12.48 | 15.56 | 34.69 |
Net Cash Growth | -8.34% | 224.55% | -19.81% | -55.13% | 23.67% |
Net Cash Per Share | 0.18 | 0.32 | 0.17 | 0.32 | 0.72 |
Filing Date Shares Outstanding | 218.5 | 184.17 | 106.41 | 48.8 | 48.14 |
Total Common Shares Outstanding | 217.51 | 182.55 | 104.9 | 48.8 | 48.14 |
Working Capital | 42.67 | 42.34 | 13.66 | 22.67 | 35.32 |
Book Value Per Share | 0.20 | 0.23 | 0.13 | 0.47 | 0.74 |
Tangible Book Value | 42.72 | 42.4 | 13.8 | 22.81 | 35.47 |
Tangible Book Value Per Share | 0.20 | 0.23 | 0.13 | 0.47 | 0.74 |